GLP1R and type 2 diabetes mellitus: According to the American Diabetes Association guidelines14 for patients with T2DM and high CVD risk, glucagon like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 inhibitors that have cardiovascular benefits are suggested as second-line treatments.